Onconova Therapeutics, Inc.
NASDAQ: ONTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Steven M. Fruchtman
- Employees
- 16
- Headquarters
- Newtown, United States
- IPO year
- 2013
- Market cap
- $624.8M
- Website
- https://www.onconova.com
Loading ONTX…
Loading profile data…Frequently asked questions about ONTX
What does Onconova Therapeutics, Inc. (ONTX) do?
Onconova Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, focused on identifying and advancing innovative therapeutic solutions for oncological diseases. The company's pipeline currently highlights two primary drug candidates undergoing clinical trials: 1. Narazaciclib (ON 123300): This is a multi-targeted kinase...
Where does ONTX trade?
Onconova Therapeutics, Inc. (ONTX) trades on the NASDAQ Capital Market.
What sector is ONTX in?
Onconova Therapeutics, Inc. (ONTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Onconova Therapeutics, Inc.?
Steven M. Fruchtman is the chief executive officer of Onconova Therapeutics, Inc. (ONTX).
Where is Onconova Therapeutics, Inc. headquartered?
Onconova Therapeutics, Inc. is headquartered in United States.
Does ONTX pay a dividend?
Onconova Therapeutics, Inc. (ONTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ONTX go public?
Onconova Therapeutics, Inc. (ONTX) completed its initial public offering in 2013.